Table 4.
Results of the effects of the synthesized benzimidazoles on VEGFR-2 inhibitory activity in the HepG2 cell line.
| Entry | Product | Amount of VEGFR-2 (ng/mL) a | % Inhibition of VEGFR-2 in HepG2 Cell Line |
|---|---|---|---|
| 1 | 6 | 37.11 ± 3.00 | 80 |
| 2 | 13a | 175.00 ± 15.65 | 5.5 |
| 3 | 13b | 177.11 ± 20.67 | 4 |
| 4 | 13c | 170.85 ± 20.38 | 8 |
| 5 | 13d | 39.90 ± 4.60 | 78 |
| 6 | 13e | 165.71 ± 18.20 | 10 |
| 7 | 13f | 41.10 ± 3.88 | 78 |
| 8 | 13g | 66.00 ± 8.35 | 64 |
| 9 | 13h | 173.80 ± 15.76 | 6 |
| 10 | 14a | 90.00 ± 8.65 | 51 |
| 11 | 14b | 72.60 ± 9.14 | 61 |
| 12 | 14c | 180.50 ± 21.00 | 3 |
| 13 | 14d | 169.12 ± 16.80 | 9 |
| 14 | 17a | 34.00 ± 4.28 | 82 |
| 15 | 17b | 40.12 ± 5.70 | 78 |
| 16 | 17c | 66.13 ± 9.11 | 64 |
| 17 | 17d | 81.70 ± 9.16 | 56 |
| 18 | 17e | 61.86 ± 7.85 | 67 |
| 19 | 17f | 158.60 ± 19.35 | 14 |
| 20 | 19a | 173.16 ± 19.66 | 6.5 |
| 21 | 19b | 168.80 ± 16.21 | 9 |
| 22 | 19c | 177.10 ± 18.80 | 4 |
| 23 | 19d | 205.71 ± 23.30 | 11 |
| 24 | 22a | 183.00 ± 19.00 | 1 |
| 25 | 22b | 160.85 ± 15.70 | 13 |
| 26 | 24a | 166.00 ± 19.50 | 10 |
| 27 | 24c | 74.18 ± 9.70 | 60 |
| 28 | 24b | 68.81 ± 8.14 | 63 |
| 29 | Sorafenib | 14.60 ± 1.02 | 92 |
| 30 | DMSO | 185.20 ± 21.85 | - |
a Data were expressed as mean ± standard error (S.E.) of two experiments.